Literature DB >> 29786486

One-year Retention of Gadolinium in the Brain: Comparison of Gadodiamide and Gadoterate Meglumine in a Rodent Model.

Philippe Robert1, Stefanie Fingerhut1, Cécile Factor1, Véronique Vives1, Justine Letien1, Michael Sperling1, Marlène Rasschaert1, Robin Santus1, Sébastien Ballet1, Jean-Marc Idée1, Claire Corot1, Uwe Karst1.   

Abstract

Purpose To compare the long-term brain elimination kinetics and gadolinium species in healthy rats after repeated injections of the contrast agents gadodiamide (a linear contrast agent) or gadoterate (a macrocyclic contrast agent). Materials and Methods Nine-week-old rats received five doses of 2.4 mmol gadolinium per kilogram of body weight over 5 weeks and were followed for 12 months with T1-weighted MRI (n = 140 rats, corresponding to seven time points, two contrast agents, and 10 rats per group). Animals were sacrificed at 1 week, 1 month, and 2, 3, 4, 5, and 12 months after the last injection. Brain and plasma were sampled to determine the total gadolinium concentration by using inductively coupled plasma mass spectrometry (ICP-MS). For the cerebellum, gadolinium speciation analysis was performed after mild extraction at four time points (1 month and 3, 5, and 12 months after the last injection) by using size exclusion chromatography and hydrophilic interaction liquid chromatography, both coupled to ICP-MS. Tissue gadolinium kinetics were fitted to estimate the area under the curves and tissue elimination half-lives over the 12-month injection-free period. Results T1 hyperintensity of the deep cerebellar nuclei was observed only in gadodiamide-treated rats and remained stable from the 1st month after the last injection (the ratio of the signal intensity of the deep cerebellar nuclei to the signal intensity of the brain stem at 1 year: 1.101 ± 0.023 vs 1.037 ± 0.022 before injection, P < .001). Seventy-five percent of the total gadolinium detected after the last injection of gadodiamide (3.25 nmol/g ± 0.30) was retained in the cerebellum at 1 year (2.45 nmol/g ± 0.35), with binding of soluble gadolinium to macromolecules. No T1 hyperintensity was observed with gadoterate, consistent with a rapid, time-dependent washout of the intact gadolinium chelate down to background levels (0.07 nmol/g ± 0.03). Conclusion After repeated administration of gadodiamide, a large portion of gadolinium was retained in the brain, with binding of soluble gadolinium to macromolecules. After repeated injection of gadoterate, only traces of the intact chelated gadolinium were observed with time-dependent clearance. Online supplemental material is available for this article.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29786486     DOI: 10.1148/radiol.2018172746

Source DB:  PubMed          Journal:  Radiology        ISSN: 0033-8419            Impact factor:   11.105


  27 in total

1.  Nonhomogeneous Gadolinium Retention in the Cerebral Cortex after Intravenous Administration of Gadolinium-based Contrast Agent in Rats and Humans.

Authors:  Olga Minaeva; Ning Hua; Erich S Franz; Nicola Lupoli; Asim Z Mian; Chad W Farris; Audrey M Hildebrandt; Patrick T Kiernan; Laney E Evers; Allison D Griffin; Xiuping Liu; Sarah E Chancellor; Katharine J Babcock; Juliet A Moncaster; Hernan Jara; Victor E Alvarez; Bertrand R Huber; Ali Guermazi; Lawrence L Latour; Ann C McKee; Jorge A Soto; Stephan W Anderson; Lee E Goldstein
Journal:  Radiology       Date:  2019-11-26       Impact factor: 11.105

2.  Comparison of the Relaxivities of Macrocyclic Gadolinium-Based Contrast Agents in Human Plasma at 1.5, 3, and 7 T, and Blood at 3 T.

Authors:  Pavol Szomolanyi; Martin Rohrer; Thomas Frenzel; Iris M Noebauer-Huhmann; Gregor Jost; Jan Endrikat; Siegfried Trattnig; Hubertus Pietsch
Journal:  Invest Radiol       Date:  2019-09       Impact factor: 6.016

3.  Comparison of ferumoxytol- and gadolinium chelate-enhanced MRI for assessment of sarcomas in children and adolescents.

Authors:  Florian Siedek; Anne M Muehe; Ashok J Theruvath; Raffi Avedian; Allison Pribnow; Sheri L Spunt; Tie Liang; Crystal Farrell; Heike E Daldrup-Link
Journal:  Eur Radiol       Date:  2019-12-16       Impact factor: 5.315

Review 4.  Standardized assessment of the signal intensity increase on unenhanced T1-weighted images in the brain: the European Gadolinium Retention Evaluation Consortium (GREC) Task Force position statement.

Authors:  Carlo C Quattrocchi; Joana Ramalho; Aart J van der Molen; Àlex Rovira; Alexander Radbruch
Journal:  Eur Radiol       Date:  2018-11-09       Impact factor: 5.315

5.  Gadolinium Retention in the Brain: An MRI Relaxometry Study of Linear and Macrocyclic Gadolinium-Based Contrast Agents in Multiple Sclerosis.

Authors:  Y Forslin; J Martola; Å Bergendal; S Fredrikson; M K Wiberg; T Granberg
Journal:  AJNR Am J Neuroradiol       Date:  2019-06-27       Impact factor: 3.825

6.  Neurologic Effects of Gadolinium Retention in the Brain after Gadolinium-based Contrast Agent Administration.

Authors:  Jennifer Ayers-Ringler; Jennifer S McDonald; Margaret A Connors; Cody R Fisher; Susie Han; Daniel R Jakaitis; Bradley Scherer; Gabriel Tutor; Katheryn M Wininger; Daying Dai; Doo-Sup Choi; Jeffrey L Salisbury; Paul J Jannetto; Joshua A Bornhorst; Ram Kadirvel; David F Kallmes; Robert J McDonald
Journal:  Radiology       Date:  2021-12-21       Impact factor: 11.105

7.  An NMR relaxometry approach for quantitative investigation of the transchelation of gadolinium ions from GBCAs to a competing macromolecular chelator.

Authors:  Patrick Werner; Matthias Taupitz; Leif Schröder; Patrick Schuenke
Journal:  Sci Rep       Date:  2021-11-05       Impact factor: 4.379

8.  The anterior eye chamber: entry of the natural excretion pathway of gadolinium contrast agents?

Authors:  Katerina Deike-Hofmann; Paula von Lampe; Heinz-Peter Schlemmer; Nikolaos Bechrakis; Christoph Kleinschnitz; Michael Forsting; Alexander Radbruch
Journal:  Eur Radiol       Date:  2020-03-16       Impact factor: 5.315

9.  Albumin-based nanoparticles as contrast medium for MRI: vascular imaging, tissue and cell interactions, and pharmacokinetics of second-generation nanoparticles.

Authors:  E A Wallnöfer; G C Thurner; C Kremser; H Talasz; M M Stollenwerk; A Helbok; N Klammsteiner; K Albrecht-Schgoer; H Dietrich; W Jaschke; P Debbage
Journal:  Histochem Cell Biol       Date:  2020-10-11       Impact factor: 4.304

10.  Repeat and single dose administration of gadodiamide to rats to investigate concentration and location of gadolinium and the cell ultrastructure.

Authors:  Julie Davies; Michael Marino; Adrian P L Smith; Janell M Crowder; Michael Larsen; Lisa Lowery; Jason Castle; Mark G Hibberd; Paul M Evans
Journal:  Sci Rep       Date:  2021-07-06       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.